Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Revenue projections:

Revenue projections for SYNGENE
Revenue projections for SYNGENE

Syngene International Limited's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 0.00000
forwardPE 41.54316
debtToEquity 12.28300
earningsGrowth -0.87400
revenueGrowth -0.02800
grossMargins 0.68297
operatingMargins 0.12943
trailingEps 8.76000
forwardEps 13.09000

SYNGENE's low Debt-to-Equity ratio means the company is not highly leveraged. This suggests a sound financial position with minimal reliance on debt, reducing risk and ensuring greater financial flexibility, making it a more stable option for investors.
SYNGENE's low earnings and revenue growth suggest that the company may face shrinking profits. This could indicate underlying financial challenges, making it difficult for SYNGENE to sustain its current profitability.
SYNGENE's negative gross and operating margins suggest that the company is currently losing money, unable to generate profit from production or operations. This could signal inefficiencies in cost control or a drop in sales.
SYNGENE's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Price projections:

Price projections for SYNGENE
Price projections for SYNGENE

SYNGENE's price projections have been revised downward gradually, indicating that analysts are tempering their expectations. This downward shift suggests a more cautious outlook on the company's growth prospects.

Recommendation changes over time:

Recommendations trend for SYNGENE
Recommendations trend for SYNGENE


Analysts have maintained a buy bias for SYNGENE, which could prompt investors to consider the stock as a viable investment. With this positive outlook, SYNGENE is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.